Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 2Unspecified Adult Solid Tumor, Protocol Specific 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Mesothelial Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Malignant Solid Tumor 1

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Resectable Esophageal Cancer × Adjuvants, Immunologic × Clear all
NCT05307835 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Active not recruiting
27 enrolled
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡